This biomarker is also known as:
- prothymosin beta-4,
- thymosin Î²4,
- thymosin beta-4,
- thymosin beta 4, X-linked,
- thymosin, beta 4, X chromosome,
- T beta-4,
View in BioMuta
TMSB4X, or thymosin beta-4, belongs to the thymosin beta family. It is an actin sequestering protein which plays an important role in the regulation of actin polymerization. TMSB4X binds to and sequesters actin monomers (G actin) and therefore inhibits actin polymerization. It is also involved in cell proliferation, migration, and differentiation. This gene escapes X inactivation and has a homolog on chromosome Y.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
Overexpression of thymosin beta-4 in tumors has been suggested to stimulate lung tumor metastasis by activating cell migration and angiogenesis. The gene expression of thymosin beta-4 was also significantly associated with metastasis in NSCLC patients and it was suggested as a prognostic parameter for NSCLC.
Thymosin beta-4 belongs to a 9-member panel that provides a quantitative measure of the probability of having lung cancer that goes beyond the histological evaluation of preinvasive lesions. The identified members of the panel are TMSB4X (Thymosin beta-4), Ubiquitin, des-ubiquitin, ACBP, CSTA, Cytochrome C, and MIF.
This biomarker is currently being annotated or is under review.
You must be logged in
or do not have permission to view any additional information. Contact Heather Kincaid at
if you should have access to this biomarker.
Update: Pre-application webinar information now available.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.